Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | GABRP | O00591 | 1/20 | 0.59 |
| ▸ | GABRD | O14764 | 1/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iclazepam SCHEMBL29388910 | 1.00 | OPRK1 (0.61) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| Prazepam SCHEMBL78272 | 0.84 | OPRK1 (0.69) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| Prazepam SCHEMBL29565880 | 0.84 | OPRK1 (0.69) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| SCHEMBL7402732 | 0.84 | OPRK1 (0.61) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| SCHEMBL26665187 | 0.83 | OPRK1 (0.59) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| SCHEMBL30661071 | 0.83 | OPRK1 (0.59) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| SCHEMBL7413320 | 0.82 | OPRK1 (0.63) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| Hydrochloric Acid SCHEMBL7408744 | 0.81 | OPRK1 (0.62) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| SCHEMBL5350856 | 0.81 | OPRK1 (0.63) | OPRK1NR1I2ADORA3OPRM1KCNH2 | |
| SCHEMBL9040148 | 0.81 | OPRK1 (0.71) | OPRK1NR1I2ADORA3OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-20 | — | — | US | disclosed |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2025-11-25 | — | — | US | disclosed |
| US-20250281535-A1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-09-11 | — | — | US | disclosed |
| EP-4401842-B1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-08-27 | — | — | EP | disclosed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4512482-A2 | DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF | Hephaistos-Pharma (FR) | 2025-02-26 | — | — | EP | disclosed |
| EP-4117790-B1 | DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF | HEPHAISTOS PHARMA (FR) | 2024-11-27 | — | — | EP | disclosed |
| WO-2021180972-A1 | DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF | HEPHAISTOS-PHARMA (FR) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021110987-A1 | METHODS AND APPARATUSES FOR DIAGNOSING CANCER FROM CELL-FREE NUCLEIC ACIDS | LIFE & SOFT (FR) | 2021-06-10 | — | — | WO | disclosed |
| US-20210061873-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2020245321-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2020-12-10 | — | — | WO | disclosed |
| US-20190161529-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2019-05-30 | — | — | US | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| EP-2593104-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | Müller, Prof. Dr., Wolfgang (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2011011692-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | STC.UNM (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | MAOB, MAOA, ME3 | OPRK1 13/4885NR1I2 1018/4885ADORA3 2157/4885 |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | OPRK1 415/4885NR1I2 3135/4885ADORA3 566/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | OPRK1 225/4885NR1I2 2295/4885ADORA3 553/4885 |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | GABRB2, GABRA4, GABRB1 | OPRK1 167/4885NR1I2 685/4885ADORA3 233/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | OPRK1 3285/4885NR1I2 4504/4885ADORA3 4067/4885 |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | MAOB, MAOA, HTR2B | OPRK1 7/4885NR1I2 580/4885ADORA3 1313/4885 |
| US-20210061873-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | OPRK1 415/4885NR1I2 3135/4885ADORA3 566/4885 |
| US-20190161529-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | OPRK1 415/4885NR1I2 3135/4885ADORA3 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.